5 ml Visomitin eye drops cataract dry eyes Active substance: 1 ml contains: plastoquinonyl decyl triphenylphosphonium bromide (PDTF) 0.155 mcg. Excipients: Benzalkonium chloride 0.1 mg, hypromellose 2 mg, sodium chloride 9 mg, sodium dihydrogen phosphate dihydrate 0.81 mg, sodium hydrogen phosphate dodecahydrate 1.16 mg, sodium hydroxide 1 M solution to pH 6.3 - 7.3, water for injection up to 1 ml. Description: Transparent or slightly opalescent, colorless or slightly colored liquid. Indications for use Dry Eye Syndrome. The initial stage of age-related cataract. Interaction with other drugs If necessary, you can apply simultaneously with other eye drops. At the same time, a break between installations should be at least 5 minutes. Overdose Data on overdose with topical application are not available. pharmachologic effect Pharmacological group: Keratoprotective agent. Antioxidant Pharmacodynamics: Plastoquinonyldecyl triphenylphosphonium bromide (PDTF) is a derivative of plastoquinone, which is linked via a linker chain (C10) to the triphenylphosphine residue. PDTF in low (nanomolar) concentrations exhibits high antioxidant activity. It also has a stimulating effect on the process of tear production, epithelization, helps to increase the stability of the tear film. One of the reasons for the development of age-related cataracts is the damaging effect of ultraviolet radiation, which initiates photooxidation processes, leading to the denaturation of the crystalline crystalline component of the lens. The first protection of eye tissues from ultraviolet radiation is a tear fluid, which absorbs ultraviolet light in the range of 240-320 nm and neutralizes it due to the components of the antioxidant activity of the tear fluid. According to preclinical studies, the anti-cataract effect of the drug Visomitin is associated with an increase in the expression level of the main lens proteins of alpha crystallins, restoration of the lens epithelium and activation of energy processes in it. According to a clinical study, in patients with age-related cataract who used the drug Visomitin, an increase in the antioxidant activity of tears was noted. Pharmacokinetics: Studies of pharmacokinetics in humans have not been conducted. In preclinical studies in animals, the distribution of PDTF in organs and tissues occurred within 48 hours after intravenous and intragastric administration. It was found that PDTF is present in the highest concentrations in the tissues of the kidney, liver and heart within 1 h after administration. PDTF undergoes relatively fast enzymatic cleavage and covalent binding to proteins. Storage conditions In the dark place at a temperature of 2-80C. Store the opened bottle in a dark place at a temperature of 2-80C; use within 1 month. Keep out of the reach of children. Dosage Dry eye syndrome: 1-2 drops of the drug in the conjunctival sac 3 times a day. The duration of treatment is determined by the doctor depending on the severity of the disease.